Personal Stories from TB Survivors - My Journey fighting TB

Molluscum Contagiosum – Symptoms, Treatments And Prevention

What is it?

Molluscum contagiosum (MC) is a viral skin infection caused by the molluscum contagiosum virus (MCV) and is highly infectious.

MCV belongs to the family of poxviruses, which infect human skin cells.

Some people are resistant to the molluscum contagiosum virus so won't become infected, even when in contact with someone who is infected. It's not known why some people are resistant and some people aren't.

What are the symptoms?

If your child has molluscum contagiosum they may have small lesions or abnormal patches on the skin that can be firm, raised and painless. The lesions usually appear in small clusters and spread widely across different parts of the body, including hands, arms, face and neck.

Some of the lesions have a tiny grey head in the centre and are pearly in appearance. This head may split, causing a thick yellowy-white substance to escape, which is highly infectious.

You and your child should avoid handling or squeezing the lesions, as this will speed up the spreading of the infection.

Each lesion will crust over in its own time and heal, up to approximately 12 weeks after it first appeared.

For about one in 10 cases, patches of eczema can develop around the lesions, according to the NHS.

How does molluscum contagiosum spread?

Molluscum contagiosum can be spread through close direct contact, such as touching the skin of someone who is infected. It's common in schools because the sharing of contaminated objects, such as toys and clothes, can spread the virus easily.

Do you need to take your child to the doctor?

Yes. Your doctor will examine your child's skin and ask about their symptoms. However, molluscum contagiosum usually clears without the need for treatment.

Should your child go to school?

Yes. It's not necessary for your child to stay home from school with molluscum contagiosum and they can continue to swim, too.

However in order to stop the infection from spreading, keep the affected areas of your child covered with clothing where possible. Make sure your child doesn't scratch the infected area because this will prolong the infection.

Wash all clothing, bedding and towels regularly at a high temperature to prevent the infection from spreading.

What else may your child come into contact with during school?

Other infections such as tonsillitis, verrucas, chickenpox, impetigo, ringworm, threadworms, ear infections, diarrhoea and vomiting are also common for your child to catch during school.

Read more:

Verrica Announces Proposed Public Offering

Verrica Pharmaceuticals Inc.

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by Verrica. Verrica intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants to purchase shares of its common stock in an amount up to 15% of the securities offered in the public offering under the same terms and conditions. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Jefferies is acting as sole book-running manager for the offering.

A shelf registration statement relating to the shares of common stock, pre-funded warrants and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission (SEC) on November 7, 2022 and declared effective by the SEC on December 19, 2022. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.Sec.Gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.Com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.

Story Continues

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and similar expressions, and are based on Verrica's current beliefs and expectations. These forward-looking statements include statements about Verrica's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica's Annual Report on Form 10-K for the year ended December 31, 2023, Verrica's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.Com

Chris CalabreseLifeSci Advisorsccalabrese@lifesciadvisors.Com

---